N/A N=8 Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention
Colorectal Cancer
Primary: Percent of Patients Receiving GI Consult for FOBT+ Results — 39; 47; 64; 51 percent patients receiving GI consult
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=88 Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds
Diabetic Foot Ulcers · Pressure Ulcers
Primary: Adequate Management of the Wound Assessed by a Left Movement (Improvement) in the Modified Bates Jensen Wound Assessment Tool. — 20.28; 21.38; 20.94; 20.59 units on a…
Phase 3 N=126 Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
Influenza
Primary: Percentages of Subjects With Seroconversion or Significant Increase in HI Titer Against Each of Three Vaccine Strains After One Vaccination of TIVc — 73; 58; 67; 45…
N/A N=943 Integrating Clinical Practice Guidelines for Smoking Cessation Into Mental Health Care for Veterans With Posttraumatic Stress Disorder
Mental Health · Stress Disorders, Post-Traumatic · Substance-Related Disorders
Primary: Bioverified 12-Month Prolonged Abstinence Between 6 and 18 Months Postrandomization — 42; 21 participants — p=0.007
Phase 3 N=99 Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures
Partial Onset Seizures
Primary: Percent Change in Partial Onset Seizure Frequency Per 28 Days From Baseline to the Double-blind Phase, by Treatment Group — -2.85; 14.82 percentage change per 28 days
N/A N=428 Evaluating a Coparenting Breastfeeding Support Intervention
Parenting · Breastfeeding
Primary: Exclusive Breastfeeding Rate at 12 Weeks Postpartum — 70; 63 percentage of participants — p=0.27
N/A N=3,939 Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
Phase 2 N=195 A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1
HIV-1
Primary: Percentage of Participants With Less Than 50 Copies Per Milliliter (Copies/mL) of Human Immunodeficiency Virus Type 1 Ribonucleic Acid (HIV-1 RNA) at Week 48 — 78.5…
N/A N=204 Oocyte Cryopreservation Registry (HOPE Registry)
Oocyte Cryopreservation
Primary: Thawing Cycle Level Live Birth Rate — 12.4; 15.0; 13.6 % of oocytes thawed per cycle
Phase 3 N=106 A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy
Hepatitis C, Chronic
Primary: The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12) — 52.8; 35.8…
Early Phase 1 N=13 Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy
Breast Cancer · Vaginal Dryness · Dyspareunia
Primary: Total Female Sexual Function Index (FSFI) Score — 8.691; 18.783 units on a scale — p=<0.0005
N/A N=22 Treadmill Training and Orthotic Use in Infants With Down Syndrome
Down Syndrome
Primary: Pattern of Gross Motor Development — 28.2; 28.3 months
Phase 2 N=151 BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
Glioma
Primary: Number of Participants With DLT- Phase I — 2; 0; 4 participants
Phase 3 N=304 Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
Japanese Encephalitis
Primary: Primary: 1. Geometric Mean Titers (GMT) at Day 56 — 100.1; 84.7; 68.1 Geometric Mean Titer - Estimate
Phase 3 N=639 Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: GMT for Anti-JEV Neutralizing Antibody — 160.71; 272.24; 127.56 GMT